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Summary. We prospectively examined whether there is an
associationbetween elevated anticardiolipin antibody levels and
the risk for a future ﬁrst venous thrombosis (VT) in a general
population. We studied this in a large population-based nested
case-cohort study of 508 VT cases and 1464 matched control
subjects from a cohort of 66 140 participants in the Health
Study of Nord-Trøndelag in Norway. Venous thrombosis was
validated using standardized criteria for venous thrombosis and
pulmonary embolism. Prethrombotic serum anticardiolipin
antibodies were measured by an enzyme-linked immunoassay.
There was no association between elevated anticardiolipin
antibody levels and subsequent venous thrombosis, overall or
after stratiﬁcation by sex, diﬀerent age groups or idiopathic vs.
secondary thrombosis. The overall odds ratio was 1.11 (95%
CI: 0.71–1.74) for greater thanvs. less than the 95thpercentile of
anticardiolipin antibody levels. In conclusion, in this general
population sample elevated anticardiolipin antibody levels was
not a risk factor for subsequent venous thrombosis.
Keywords: anticardiolipin antibodies, antiphospholipid anti-
bodies, population-based, prospective study, pulmonary
embolism, venous thrombosis.
Introduction
Antiphospholipid antibodies are a wide and heterogeneous
group of antibodies, formerly believed to react to negatively
charged phospholipids [1]. In recent years they have been
shown to be directed against plasma proteins bound to anionic
(not necessarily phospholipid) surfaces. Antibodies against b2-
glycoprotein I (b2-GPI) and prothrombin are the two best
known [2–4], and are detected in anticardiolipin antibody
assays and in most lupus anticoagulant assays [2,5]. The
persistent presence of these antibodies, in two following tests at
least 6 weeks apart, in combination with arterial and venous
thrombosis, or recurrent fetal loss deﬁnes the antiphospholipid
syndrome [6,7]. The syndrome is termed primary antiphosp-
holipid syndrome when there is no evidence of underlying
disease, and secondary in the setting of autoimmune diseases,
mainly systemic lupus erythemathosus [8].
Elevated anticardiolipin antibody levels have been associated
with a twofold increased risk of venous thrombosis in presence
of autoimmune disease (mainly systemic lupus erythematho-
sus) [9,10].
In patients without autoimmune disease the association
between anticardiolipin antibodies and risk of venous throm-
bosis has been inconsistent [11–17].
A meta-analysis of primarily case-control studies showed
that the presence of anticardiolipin antibodies carried an odds
ratio for venous thrombosis ranging from 0.3 to 2.5 regardless
of site (arterial or venous), type (ﬁrst event or recurrent) or the
presence of systemic lupus erythemathosus [18]. Higher levels
of anticardiolipin antibodies were associated with higher risk
for venous thrombosis [18].
Amajor limitation of most of the studies published to date is
that anticardiolipin antibodies were measured in blood collec-
ted after the thrombosis. Transiently elevated anticardiolipin
antibody levels are found in many patients after a venous
thrombosis, suggesting that the antibodies may be a result
rather than a cause of thrombosis in these patients [19].
Only two prospective studies, measuring anticardiolipin
antibodies in blood collected before the venous thrombosis
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occurred in persons without autoimmune diseases, have been
published [20,21]. The ﬁrst study, in male physicians, showed
an association for a ﬁrst venous thrombosis within the 5%
highest immunoglobulin (Ig)G anticardiolipin antibody levels.
The second study, which is the only population-based
prospective study published, reported no association with
different levels of anticardiolipin antibodies.
The aim of our study is to assess whether the presence of
anticardiolipin antibodies is related to the risk of subsequent
ﬁrst venous thrombosis in a general population. Most studies
published are concerned with the risk of recurrent thromboses
in selected patient populations, and have measured anticard-
iolipin antibodies after the events. In contrast we have studied
the risk for ﬁrst events in an unselected population, and studied
the relation prospectively by measuring anticardiolipin anti-
bodies in blood samples collected prior to the events.
Methods
Study design
We included all cases with a validated diagnosis of a ﬁrst
venous thrombosis that occurred during a 7 year follow-up of
the second Health Study of Nord-Trøndelag (HUNT 2)
cohort, as well as controls selected at enrolment of the same
cohort in a nested case cohort design.
The HUNT 2 cohort
The entire population (n ¼ 94 194) of the Nord-Trøndelag
County inmiddle Norway, at the age of 20 years and older was
invited to participate in the population-basedHUNT2 study in
1995 [22]. The population of Nord-Trøndelag County has a
demographic composition similar to the general population of
Norway and a low geographic mobility, which makes it well
suited for a population survey. HUNT 2 is a comprehensive
health study covering a wide range of topics, such as chronic
diseases, mental diseases, medication, education, employment,
physical activity and quality of life. Seventy-one per cent of the
whole population (n ¼ 66 140), with a median age of 46 years
(range 19–103) were enrolled in the period 1995–1997. Data
were collected by questionnaires, clinical measurements and
blood samples at inclusion.
Cases
We included all individuals registered with a ﬁrst venous
thrombosis, i.e. deep vein thrombosis or pulmonary embolism
in the Nord-Trøndelag County from 1995 through 2001. All
patients with venous thrombosis in the county were diagnosed
and treated in Levanger hospital andNamsos hospital, the only
two hospitals in the region. We collected the patients through
the computerized diagnosis registry of the two hospitals by
ICD-9 and ICD-10 diagnostic codes for venous thrombosis
(see Appendix). Two-thousand-and thirty-six cases with a
diagnostic code of venous thrombosis were thus identiﬁed.
Hospital records were obtained and venous thrombosis
diagnoses validated for each case by two physicians (IAN,
SCC). Cases were only included for this analysis when they
fulﬁlled the following criteria: for deep vein thrombosis having
an intraluminal ﬁlling defect or no venous ﬁlling on ascending
contrast venography; non-compressible venous segment or no
venous ﬂow in popliteal, femoral or axillar veins on duplex
ultrasound; a positive CT scanning or a positive autopsy; for
pulmonary embolism having ventilation-perfusion scans with
one or multiple segmental or subsegmental perfusion defects
with normal ventilation; a contrast defect on pulmonary CT
scanning or a positive autopsy. Cases were also classiﬁed as ﬁrst
or recurrent events, and as idiopathic or secondary. An event
was classiﬁed as idiopathic when no obvious cause was
registered in the medical record within the last 3 months before
the event. A secondary event was registered when a major
trauma (speciﬁed with or without fracture to truncus, spine,
pelvis, lower limb, upper limb, head, or other locations), major
surgery (speciﬁed as orthopedic-, abdominal-, gynecological-,
urological-, or other kind of surgery), marked immobility
(speciﬁed as paresis, paralysis, or > 8 h travel) within the last
3 months, obstetric cause (as pregnancy or delivery) within the
last 2 weeks, oral contraceptive pills used at the time of or
within 1 month before the venous thrombosis, or a malignancy
was registered in the patient history. We identiﬁed 1226 cases
with an objectively veriﬁed diagnosis of venous thrombosis.
The records were linked to the HUNT 2 cohort and 798
cases were identiﬁed within the cohort. Of these cases, 283
cases were excluded for the following reasons: previously
diagnosed venous thrombosis, i.e. venous thrombosis before
enrolment in the HUNT 2 study, or venous thrombosis
located in the eye. Of the 515 cases included, blood samples
were missing in 7 (1.4%). Thus the ﬁnal study population
consisted of 508 cases with a ﬁrst venous thrombosis occurring
after entry in the HUNT 2 study.
Controls
Control subjects were selected at random from the baseline of
the HUNT 2 study. The controls were frequency matched to
the cases by sex and 5 year age strata. We selected 1505
controls. The controls were excluded for the same reasons as
the cases (previously diagnosed venous thrombosis, i.e. venous
thrombosis before enrolment in the HUNT 2 study, or venous
thrombosis located in the eye). Medical records were reviewed
for both cases and controls after in- and out-patient diagnosis
registries had been scanned for ICD-9 diagnostic codes for
venous thrombosis (see Appendix) before entry of theHUNT 2
study. Thus 29 controls with a previous venous thrombosis
(venous thrombosis before entry of the HUNT 2 study) were
excluded, leaving 1476 individuals as control subjects. Blood
samples were missing in 12 (0.8%) control subjects, leaving
1464 controls for the analyses. Another 29 controls had a ﬁrst
venous thrombosis during the follow-up and they were
included both in the 508 cases and the 1464 controls in the
analyses.
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Laboratory methods
Whole blood was drawn from non-fasting participants at
HUNT 2 entry, centrifuged within 2 h, and the serum
immediately placed in a refrigerator at 4 C. The samples were
sent in a cooler to the central laboratory in Levanger the same
day and stored in the HUNT biobank at )70 C. After
selection of cases and controls, stored samples from theHUNT
biobank were retrieved.
Serum anticardiolipin antibodies were measured by a
commercial sandwich enzyme linked immunosorbent assay
(ELISA), the Varelisa Cardiolipin Screen test (Pharmacia
Diagnostics, Uppsala, Sweden). The assay is adjusted to a set of
established standard sera [23]. The test detects patient serum
IgG, IgM and IgA antibodies to b2-GPI bound to immobilized
cardiolipin.
Plastic microtiter plates, coated with b2-GPI from bovine
heart in complex with bovine heart cardiolipin were incubated
for 30 min with 100 lL of diluted [1 : 100 in phosphate-
buffered saline (PBS)] patient samples, a negative control and a
calibrator. After washing three times with a PBS buffer
containing 0.1%sodiumazide (NaN3), thewellswere incubated
for 30 min with enzyme (horseradish peroxidase) labeled
secondary antibodies to human IgG, IgM and IgA. After
washing three times, the wells were incubated in the dark for
10 min with the substrate 3, 3¢, 5, 5¢ tetramethylbenzidine. Ten
minutes after a stop solution (H2SO
)4) was added,wemeasured
optical density (OD) at 450 nm in a spectrophotometer. The
calibrator sample determined the OD cut-off value for each kit.
The calculation of the cut-off, suggested by the manufacturer,
was based on 432 apparently healthy blood donors. The results
were expressed in screening ratios, calculated fromOD sample/
OD cut-off. The manufacturer’s suggestions for interpretations
of the results were anticardiolipin antibody screening ratio£ 1.0
as negative, 1.0–1.2 as low positive and ‡ 1.2 as high positive.
In a subsequent analysis we measured IgG anticardiolipin
antibody (Varelisa Cardiolipin IgG) and IgM anticardiolipin
antibody (Varelisa Cardiolipin IgM) separately in the 59
samples that had a positive anticardiolipin antibody screening
ratio (ratio > 1.0). These speciﬁc tests use the same ELISA
technique as the screening test, but express the result in
anticardiolipin antibody concentrations calibrated to a stand-
ard curve for each kit. The technicians were blinded to whether
the samples came from patients or control subjects.
Statistical analysis
In a univariate logistic regression model odds ratios and their
95% conﬁdence intervals were calculated for the quintiles of
anticardiolipin antibody levels and three cut-off levels, the 90th,
the 95th, and the 98th percentile separately. The percentiles
were calculated from the distribution in the control subjects.
Subsequently, we stratiﬁed for sex, different age categories,
type of thrombosis (idiopathic or secondary) and time between
blood sampling and event, in order to evaluate a possible effect
in some subgroups only.
Ethics
All participants gave their informed consent at enrolment in the
HUNT 2 study. Each surviving adult HUNT 2 participant
(n ¼ 61 426) received an information folder and a personal
letter asking for a new consent to include genetic research in
2002. One thousand one hundred and eighty-ﬁve persons
(1.9%) withdrew from the cohort. The current case–cohort
study was approved by the National Data Inspectorate and the
Regional Ethical Committee.
Results
Participants
Table 1 shows the general characteristics of the 508 patients
and 1464 control subjects. Most cases were elderly (50%
> 70 years old) and few were younger than 50 years old
(16%). The median age of both cases and controls at baseline
was 70 years (range 20–98). Fifty-ﬁve per cent of both patients
and control subjects were women. Two-thirds of the patients
had deep venous thrombosis and one-third pulmonary embol-
ism. Among the 508 events, 245 were idiopathic venous
thrombosis and 263 secondary according to the criteria
described in the method section.
Anticardiolipin antibodies
The distribution of the anticardiolipin antibody levels was
highly skewed with most of the observations at the very low
levels (Fig. 1). The median anticardiolipin antibody screening
ratios for cases and controls were 0.386 and 0.376, respectively,
and the distributions were very similar. The 90th, 95th and 98th
Table 1 General characteristics of the study population
Patients [n (%)] Controls [n (%)]
Total 508 1464
Sex
Men 228 (44.9) 673 (46.0)
Women 280 (55.1) 791 (54.0)
Age groups
20–29 12 (2.4) 30 (2.0)
30–39 17 (3.3) 47 (3.2)
40–49 53 (10.4) 145 (9.9)
50–59 73 (14.4) 197 (13.5)
60–69 99 (19.5) 301 (20.6)
70–79 169 (33.3) 498 (34.0)
> 80 85 (16.7) 246 (16.8)
Event
DVT 322 (63.4) 15 (51.7)*
PE 153 (30.1) 12 (41.4)*
Both 33 (6.5) 2 (6.9)*
Time from blood sample to event
Median (range) 33 months (2 days to 75 months)
*The controls were collected at the entry of the HUNT 2 study. During
the follow-up, i.e. after the blood sampling at the entry, 29 controls got
a ﬁrst VT. They are included both as cases and controls. Controls with
previous events, i.e. events before the entry of the cohort, were
excluded. DVT, deep vein thrombosis; PE, pulmonary embolism.
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percentiles calculated from the distribution in the control
subjects were 0.675, 0.837 and 1.169, respectively.
Forty-six (78%) of the 59 subjects with positive anticardi-
olipin antibody screening levels (ratio ‡ 1.0) had elevated
anticardiolipin IgG or IgM present in the speciﬁc tests, with an
IgG/IgM ratio of 2 : 1. The IgG/IgM ratio was 5 : 1 in those
with high anticardiolipin antibody screening levels
(ratio ‡ 1.2).
Association with venous thrombosis
We observed no statistically signiﬁcant associations between
quintiles of anticardiolipin antibody levels and venous throm-
bosis (Table 2). Using cutoffs according to the 95th, 98th and
99th percentiles of anticardiolipin antibody levels, calculated
from the distribution in the controls, no signiﬁcant effect could
be demonstrated, overall or in men and women separately
(Table 3). However, the odds ratios tended to be higher in
women than men. Further stratiﬁcation showed no signiﬁcant
associations within subsets of patients, including idiopathic or
secondary venous thrombosis, or different time between blood
sampling and the event, i.e. even in those with high anticard-
iolipin antibody levels the risk of venous thrombosis was not
increased in the time immediately following the blood sampling
(Table 4). The results did not change notably when we used the
98th percentile as a cutoff. However, high anticardiolipin
antibody levels appeared to have some effect (albeit non-
signiﬁcant) on the risk of venous thrombosis in the youngest
age group (< 50 years old).
Discussion
This large prospective population-based study shows no
evidence of an association between the presence of anticard-
iolipin antibodies and subsequent occurrence of ﬁrst venous
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Fig. 1. Distribution of anticardiolipin antibody levels in the study popu-
lation (n ¼ 1972).
Table 2 Odds ratios (OR) and 95% conﬁdence intervals (CI) for venous
thrombosis associated with quintiles of anticardiolipin antibody screening
ratio (ACA)
Quintiles of
ACA
No. of
cases
No. of
controls
Crude
OR
Adjusted
OR* 95% CI
< 0.288 116 292 1.00 1.00 Reference
0.289–0.343 84 291 0.73 0.73 0.53–1.01
0.344–0.413 85 295 0.73 0.73 0.53–1.01
0.414–0.542 118 293 1.01 1.03 0.76–1.40
‡ 0.543 105 293 0.89 0.92 0.67–1.23
*Adjusted for age and gender.
Table 3 Odds ratios (OR) and 95% conﬁdence intervals (CI) for venous
thrombosis in relation to the 95th, 98th and 99th percentiles (perc.) of
anticardiolipin antibody levels
Cutoﬀ
Cases (%)
n ¼ 508
Controls (%)
n ¼ 1464 OR 95% CI
Overall (n ¼ 1972)
£ 95th perc. 480 (94.5) 1391 (95.0) 1*
0.71–1.74> 95th perc. 28 (5.5) 73 (5.0) 1.11
£ 98th perc. 500 (98.4) 1435 (98.0) 1*
0.36–1.74> 98th perc. 8 (1.6) 29 (2.0) 0.79
£ 99th perc. 501 (98.6) 1450 (99.0) 1*
0.58–3.61> 99th perc. 7 (1.4) 14 (1.0) 1.45
Men (n ¼ 901)
£ 95th perc. 217 (95.2) 632 (93.9) 1*
0.40–1.55> 95th perc. 11 (4.8) 14 (6.1) 0.78
£ 98th perc. 225 (98.7) 658 (97.8) 1*
0.17–2.04> 98th perc. 3 (1.3) 15 (2.2) 0.56
£ 99th perc. 226 (99.1) 665 (98.8) 1*
0.16–3.49> 99th perc. 2 (0.9) 8 (1.2) 0.74
Women (n ¼ 1071)
£ 95th perc. 263 (93.9) 759 (96.0) 1*
0.84–2.81> 95th perc. 17 (6.1) 32 (4.0) 1.53
£ 98th perc. 275 (98.2) 777 (98.2) 1*
0.36–2.83> 98th perc. 5 (1.8) 14 (1.8) 1.01
£ 99th perc. 275 (98.2) 786 (99.2) 1*
0.72–7.86> 99th perc. 5 (1.8) 6 (0.8) 2.38
The 95th, 98th, and 99th percentiles are ACA screening ratio 0.837,
1.169 and 1.369, respectively. The percentiles are calculated from the
distribution in the control subjects. The same percentiles are used in
men and women.
*Reference group.
Table 4 Odds ratios (OR) with 95% conﬁdence interval (CI) for venous
thrombosis (VT) in subgroups with anticardiolipin antibody levels above
the 95th percentile compared with those below
Subgroup (n cases) Cases (%) Controls (%) OR 95% CI
Overall (508)* 28 (5.5) 73 (5.0) 1.11 0.71–1.74
Idiopathic VT (245)* 17 (6.9) 73 (5.0) 1.42 0.82–2.45
Secondary VT (263)* 11 (4.2) 73 (5.0) 0.83 0.44–1.59
< 50 years (82) 4 (4.9) 4 (1.8) 2.80 0.68–11.45
50–69 years (172) 7 (4.1) 17 (3.4) 1.20 0.49–2.95
‡ 70 years (254) 17 (6.7) 52 (7.0) 0.96 0.54–1.69
Time between blood sampling and VT
0–1 year (89)* 3 (3.4) 73 (5.0) 0.67 0.21–2.15
0–3 years (190)* 9 (4.7) 73 (5.0) 0.97 0.47–1.93
0–5 years (229)* 16 (7.0) 73 (5.0) 1.43 0.82–2.51
The 95th percentile is ACA screening ratio 0.837, calculated from the
distribution in the controls (n ¼ 1464).
*Number of controls ¼ 1464.
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thrombosis in a general population. Neither did the study
indicate any substantial effect in subgroups deﬁned by age, sex,
idiopathic vs. secondary thrombosis, or follow-up time between
the blood sample and the event.
Our results conﬁrm those of the Longitudinal Investigation
Thromboembolism Etiology (LITE) study [21]. They found no
associationbetween anticardiolipin antibodies present at cohort
entry and the risk of subsequent ﬁrst venous thrombosis with an
odds ratio of 0.66 (95% CI: 0.34–1.28) for anticardiolipin
antibody IgG levels above 95th percentile compared with those
below. There was no effect in relation to different anticardio-
lipin antibody levels or in subgroups. The study design and
anticardiolipin antibody assay used were similar to our study.
Both studies were performed in a general population, with large
sample sizes, anticardiolipin antibodies weremeasured in blood
samples drawn before the event and both used standardized
sandwich ELISA commercial kits that detect anticardiolipin
antibodies that react to b2-GPI bound to cardiolipin.
Our results contrast, however, to the Physicians Health
Study [20]. This study showed a signiﬁcant association between
anticardiolipin antibody IgG and risk of venous thrombosis in
high anticardiolipin antibody levels only. The risk ratio was 5.3
(95% CI: 1.55–18.3) for anticardiolipin antibody levels above
the 95th percentile compared with those below the 90th
percentile. The effect was not present for anticardiolipin
antibody IgG levels in tertiles above the low positive cutoff
(1.0 gamma-phospholipid [GPL] units), compared with those
below the cutoff. Unlike our study this study was derived from
a clinical trial, selected by sex, age, occupation and previous
disease occurrence, and had a small sample size. They did not
use a b2-GPI-dependent assay to detect the anticardiolipin
antibodies, possibly detecting a different subset of antibodies.
Recent reviews recommend for clinical practice assays detecting
anticardiolipin antibodies binding to b2-GPI immobilized on
cardiolipin, as used in our study, as these aremore reproducible
and better correlated with venous thrombosis in patient
populations [24,25].
Our study also contrasts to The Leiden Thrombophilia
Study (LETS) that showed a 2.4-fold increased risk for a ﬁrst
venous thrombosis with positive anti-b2-GP1-antibodies [26].
This study differs from ours by its retrospective design, with
antibodies measured in blood collected after the thrombosis.
The LETS study used a speciﬁc anti-b2-GPI assay where the
antibodies bind to puriﬁed human b2-GPI in absence of
cardiolipin or other proteins, which differs from our assay. The
conﬂicting results to our study could also be due to a different
age distribution in the two studies, as the patients in the LETS
study were younger than in our study (16–70 years, median age
45 years).
Possibly, high anticardiolipin levels have an effect in young
people only. We observed a tendency in that direction in our
study, but because of small numbers in the younger age groups,
statistical power may have been to low to say much about
subgroup effects here.
Anticardiolipin antibody assays are difﬁcult to standardize
and suffer from poor reproducibility [25]. We chose to use a
commercial anticardiolipin antibody assay that is common to
clinical practice, and which closely follows the consensus
criteria of the European Antiphospholipid Forum [25]. The
cutoff between a positive and negative anticardiolipin
antibody test is arbitrary, and statistically determined in
deﬁned test populations. Calibration against Harris standard
sera does not prevent large interlaboratory variations in results
[25]. We chose to present the results of comparison of cases and
controls at different anticardiolipin antibody levels, based on
percentiles calculated from the distribution in the control
subjects, which led to the same results as when the manufac-
turer’s cutoff was used.
Anticardiolipin antibody levels may be transient in healthy
populations [27], and an associated risk for venous thrombosis
might be transient as well. A recent study showed that 79% of
patients with idiopathic venous thrombosis that had elevated
anticardiolipin antibodies within 1 month after the thrombosis
reverted to normal after repeated testing beyond 1 month [19].
This suggests that anticardiolipin antibodies may be a result of,
rather thanacauseof the thrombosis inmanypatients.Thismay
explain the association between anticardiolipin antibodies and
venous thrombosis in retrospective studies. Duplicate testing is
included in the classiﬁcation criteria for antiphospholipid
syndrome to overcome this. We only measured anticardiolipin
antibodies once and this is a potential limitation of our study.
The diagnosis of venous thrombosis is difﬁcult, and clinical
diagnosis is unreliable [28]. We validated carefully each
individual case identiﬁed from the diagnosis registries, and
included only cases with an objectively veriﬁed diagnosis. Thus
a signiﬁcant number of potential cases that had a clinical
diagnosis with no or insufﬁcient diagnostic tests performed
were not included. A bias could theoretically result if these
cases had anticardiolipin antibody levels different from the
included cases, which is extremely implausible.
The negative results of this study cannot be extrapolated to
populations of patients with previous venous thrombosis or
autoimmune disease, where the association between anticard-
iolipin antibodies and risk for venous thrombosis is well
established [18].
It is important to address the validity and generalizability of
our study in the view of conﬂicting results from previous
studies on presence of anticardiolipin antibodies and risk for
venous thrombosis. Our results were obtained by examining a
large number of venous thrombosis events that occurred after
blood samples were collected in an unselected, large popula-
tion. We used a commercial test for b2-GPI-reactive anticard-
iolipin antibodies chosen to closely resemble the situation in
clinical practice.We thus feel that our results can be generalized
to the primary health care setting, in a general population.
In conclusion, our prospective study shows no evidence of an
association of elevated anticardiolipin antibody levels and risk
for a subsequent ﬁrst venous thrombosis. Our study does not
support measuring anticardiolipin antibodies in primary risk
evaluation of venous thrombosis nor primary anticoagulant
prophylaxis for venous thrombosis in healthy individuals with
elevated anticardiolipin antibody levels.
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Appendix
The ICD-9 codes for venous thrombosis diagnoses used were
415, 451, 452, 453, 997.2, 674, 673, 671, 634, 557, 437, 325 and
362.3 and the ICD-10 codes I26, I80, I81, I82, I67, I 63, K55,
K75, O08, O22, O87, O88 and H34.8.
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